Beijing Aosaikang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of active pharmaceutical ingredients and formulations in China. It also offers digestive health products, which include pump inhibitors suitable for various digestive tract-related diseases, such as peptic ulcers, reflux esophagitis, and upper gastrointestinal bleeding; and anti-tumor products, in...
Beijing Aosaikang Pharmaceutical reported revenue of 1.78 billion CNY for fiscal year 2024, up 23.2% from fiscal year 2023, and net income of 160.29 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 498.86 million CNY, up 5.2% from a year before. Its largest business segment, Anti-Tumor, brought in 41% of segment revenue in fiscal year 2025.
Figures from company filings; latest fiscal year ended December 31, 2024.
No profile data available.